Two vaccines, one pandemic: Retrospective insights into Covishield and Covaxin effectiveness

Background: Considering the emergence of new variants, it becomes essential to know the dynamics of the antibody profile for coronavirus disease 2019 (COVID-19) disease and its protective efficacy provided by the vaccines. Aims and Objectives: Comparing the Covishield and Covaxin jabbed COVID-19 patients in terms of clinical presentation, disease severity, and in-hospital outcome. Materials and Methods: Data were collected from the Electronic Medical Record and Bed Head Ticket during March 2021 to February 2022 and compared considering clinical profile, disease severity, and in-hospital outcome, such as survival or mortality for each arm. Results: The majority (72%) of Covishield (CV) group had added risk factors and comorbidities in comparison to 42.6% in Covaxin (CS) group. The median length of hospital stay is <7days in both arms. The Median age in years in CS arm and CV arm was 54.23 and 60, respectively. Vaccine doses and comorbidities had no statistically significant association with supplemental oxygen requirement at presentation. 93% patients had normal sensorium in the CS arm, in contrast to 82.6% in the CV arm. The number of doses and presence of comorbidities had a statistically significant association with altered sensorium. The difference between the two arms for both the CURB-65 and quick sequential organ failure assessment scores was statistically significant. Conclusion: Both vaccines show almost similar efficacy in terms of clinical presentation and in-hospital outcome. The CV group had statistically significant added risk factors and comorbidities compared to the CS arm. Furthermore, the CS arm showed less severity in terms of sensorium compared to the CV arm. The number of vaccine doses and comorbidities had a statistically significant association with altered sensorium.